SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
MEDX ... anybody following?
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
2240 62 0 MEDX
Emcee:  Ed Offstein Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2165New biological therapy Ilaris® approved in US to treat children and adults Icebrg-6/18/2009
2164One-year Phase III Study Confirms Ilaris(R) Offers Long-term Remission In PatienIcebrg-6/13/2009
2163GAME-CHANGING TRIAL The most important test case for Vasella's ideas may tuIcebrg-6/13/2009
2162Why so little market love for the PII results ?nigel bates-6/1/2009
2161Medarex Announces Efficacy Data in Cancer Patients Treated with Investigational Icebrg-6/1/2009
2160Medarex to Host Clinical Program Update Conference Call on Tuesday, June 2, 2009tnsaf-5/31/2009
2159Results from Three Phase 2 Studies Reported a Two-Year Survival Rate Ranging froIcebrg-5/31/2009
2158Pfizer and Celldex Therapeutics Present Update on CDX-110 (PF-04948568) Phase 2 Icebrg-5/30/2009
2157movers, shakers...... Message 25678459 from last 10-K..... <i>Celldex scaram(o)uche-5/29/2009
2156Medarex Announces Allowance of Investigational New Drug Application for Wholly-Otnsaf-5/28/2009
2155Relationship between pharmacokinetics and safety of tremelimumab in patients witkenhott-5/15/2009
2154ASCO 2009: Ipilimumab abstractsearch.asco.org tremelimumab, PFE abstractsearkenhott-5/15/2009
2153Ipilimumab linked to melanoma survival: studies Thu May 14, 2009 6:01pm EDT LOtnsaf-5/15/2009
2152Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody PhasIcebrg-5/14/2009
2151Can a Vaccine Prevent Brain Cancer Recurrence? By NewYork-Presbyterian Hospital/Icebrg-5/12/2009
2150For this mom, it’s about love and trust. Karen Anderson’s cancer diagnosis meanIcebrg-5/10/2009
2149Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels ofIcebrg-5/10/2009
2148PD-1 signaling on chronic myeloid leukemia-specific T cells results in T cell exIcebrg-5/9/2009
2147Abbott Sues Johnson & Johnson Over New Simponi Drug ( By Susan Decker and ShIcebrg-5/5/2009
2146FDA Advisory Committee to Review Arzerra(TM) (Ofatumumab) Summary: the FDA'stnsaf-5/5/2009
2145<i>Here is some information on non-fucosylated antibodies that may be of itnsaf-5/1/2009
2144In vitro and In vivo Characterization of MDX-1401 for Therapy of Malignant LymphIcebrg-4/30/2009
2143FDA clears potential blockbuster arthritis drug FDA clears Johnson & JohnsonIcebrg-4/25/2009
2142PD-1 Is a Regulator of NY-ESO-1-Specific CD8+ T Cell Expansion in Melanoma PatieIcebrg-4/23/2009
2141Medarex Announces Preclinical Data from Multiple Research Programs DemonstratingIcebrg-4/21/2009
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News